3 Board of Directors

The Board of Directors is responsible for PolyPeptide’s overall direction and oversight of management, and holds the ultimate decision-making authority, with the exception of matters reserved for shareholders.

We believe that the composition of our Board of Directors should reflect PolyPeptide’s objectives, strategic requirements, geographical reach and its culture. The Board of Directors should further be diverse in terms of age, gender, nationality, geographical / regional background and business experience.

In furtherance of this, the Board of Directors has determined a wide range of skills to ensure that all members are well qualified, committed and willing to devote the necessary time and effort to effectively perform their responsibilities. Based on the defined set of competencies, the Board members were asked to identify their key skills highlighted by their educational and professional background and personal achievements, as illustrated in the chart below.

Board skills distribution (as of 31 December 2024)

The Remuneration and Nomination Committee regularly assesses the set of competencies as well as each Director’s contributions to ensure that an appropriate mix of skills, expertise and diversity is represented on the Board of Directors and its Committees. In addition, the Remuneration and Nomination Committee, together with the Board of Directors, actively considers the key skills illustrated above, as well as gender diversity, in succession planning of the Board of Directors as well as of the Executive Committee.

3.1 Members of the Board of Directors

During the reporting period, the number of members of the Board of Directors decreased from seven (7) to six (6). Six (6) Directors in office as of 1 January 2024 stood for re-election at the general meeting 2024 held on 10 April 2024 (“AGM 2024”) and were approved by the shareholders. Dorothee A. Deuring was elected as a member of the Board of Directors at the general meeting 2023 and decided not to stand for re-election as a member of the Board of Directors at the AGM 2024.8 Thus, as of 31 December 2024, the Board consisted of six (6) non-executive Directors (including the Chair and the Lead Independent Director), four (4) of which are independent, as outlined below:

Name

Position

First election

End of term

 

 

 

 

Peter Wilden

Chair, Non-executive 1

2021

AGM 2025

Patrick Aebischer

Vice-Chair, Non-executive and Lead Independent Director 2, 3

2021

AGM 2025

Jane Salik

Member, Non-executive and Independent 2

2021

AGM 2025

Erik Schropp

Member, Non-executive 4

2021

AGM 2025

Beat In-Albon

Member, Non-executive and Independent 2

2021

AGM 2025

Philippe Weber

Member, Non-executive and Independent 2, 5

2021

AGM 2025

1 Due to Dr. Wilden’s prior roles within the Ferring Group and the Group’s ongoing business relationship with the Ferring Group, which is considered a related party, Dr. Wilden has been assessed as not independent. Dr. Wilden has concluded all his mandates at Ferring Group by the end of 31 December 2024. For further information, please refer to Dr. Wilden’s biography below.
2 The term “independent” is interpreted in accordance with art. 15 of the Swiss Code of Best Practice for Corporate Governance. In addition, section 4(d) of the Organizational Regulations further specifies that (i) a Director shall be deemed to have no or comparatively minor business relations with any member of the Group as long as such Director is not receiving more than CHF 120,000 during any 12-month period in direct compensation from any member of the Group (other than director fees and related compensations), and (ii) the Director is not a current executive officer of a company that made payments to, or received payments from any member of the Group for property or services in an amount which, in any of the last three fiscal years, exceeded the greater of CHF 200,000 or 5% of the recipient company’s consolidated gross revenues for that year, and (iii) the Director has not held any executive position within the Company during the past three years, and (iv) the Director does not represent a shareholder that holds more than 15% of the Company’s shares.
3 Dr. Patrick Aebischer has been a Senior Partner and member of the Investment Advisory Committee of NanoDimension Management Limited since 2017. In 2021, PolyPeptide committed to a limited investment in a partnership managed by NanoDimension Management Limited. Dr. Aebischer abstained from voting on this item. The indirect business relationship between PolyPeptide and Dr. Aebischer resulting from this commitment is considered comparatively minor. Thus, Dr. Aebischer is regarded as independent within the meaning of art. 15 Swiss Code of Best Practice for Corporate Governance and section 4(d) of the Organizational Regulations.
4 Currently, Mr. Schropp is CEO of Esperante Investments Group and a director of Draupnir Holding B.V. (one of the Company’s significant shareholders, see section 1.2 “Significant shareholders” of this Corporate Governance Report, and also a related party). As a result of these roles, Mr. Schropp is assessed as not independent. For further information, please refer to Mr. Schropp’s biography below.
5 Mr. Weber is a Partner at Niederer Kraft Frey AG (NKF); see section 4.2 “Compensation of the Board of Directors” of the Remuneration Report 2024 for disclosure of the fees paid to NKF for legal services in relation to ongoing corporate legal matters in 2024. The business relationship between PolyPeptide and NKF is considered minor. Thus, Mr. Weber is regarded as independent within the meaning of art. 15 Swiss Code of Best Practice for Corporate Governance and section 4(d) of the Organizational Regulations.

PolyPeptide believes that the composition of its Board of Directors and Committees with regard to independence and competences fairly reflects and balances the interests of its shareholders and other stakeholders.

8 Dorothee A. Deuring left the Board on 10 April 2024. For further information see section 3 “Board of Directors” of the Corporate Governance Report 2023.

Set out below is a short description of the business experience, education and activities of each director.

graphic

Peter Wilden

Chair since 2021
Non-executive9
Nationality: German
Year of birth: 1957

Professional background

Beginning in 1991, Dr. Wilden held various senior roles within the Ferring Group, ultimately serving as Executive Vice President and CFO of Ferring Pharmaceuticals between 2000 and 2017. During his tenure with the Ferring Group, Dr. Wilden also served as member of the board of directors for various subsidiaries of the Ferring Group. Following his resignation as Executive Vice President and CFO in 2017, Dr. Wilden held various directorships and advisory roles within the Ferring Group. Due to Dr. Wilden’s prior roles within the Ferring Group and the Group’s ongoing business relationship with the Ferring Group, which is considered a related party, Dr. Wilden has been assessed as not independent. Dr. Wilden has concluded all his mandates at Ferring Group by the end of 31 December 2024.10

Prior positions at PolyPeptide

  • Group Executive Chair (30 January 2023–30 September 2023)

Outside mandates at listed companies

  • None

Outside mandates at non-listed companies

  • None

Outside mandates at non-profit organizations

  • Member of the board of directors of the Suisse Polar Foundation, Switzerland (since 2018)
  • Chair of the board of directors of Project HOPE Suisse International Foundation, Switzerland (since 2015)
  • Member / Vice-Chair of the board of directors of Project HOPE, US (since 2012)

Former outside activities and functions

  • Member of the board of directors of Ferring International Center SA, Switzerland (2002–December 2024, Executive Chair 2002–December 2023)
  • Vice-Chair of the board of directors of Schlumberger AG, Austria (2014–2022)
  • Member of the board of directors of Ferring Ventures SA (previously named Trizell Holding SA), Switzerland (2014–June 2021)
  • Member / Chair of the Audit Committee / Vice-Chair of the board of directors of Lonza Group AG, Switzerland (2004–2014)
  • Executive Vice-President and CFO of Ferring Pharmaceuticals, Switzerland (2000–2017)
9 Dr. Peter Wilden assumed the role of Executive Chair on 30 January 2023 following the resignation of the then current CEO. Upon the appointment of Juan José González as CEO effective 12 April 2023 and the completion of his introduction to PolyPeptide, Dr. Wilden stepped down from his executive duties as of 30 September 2023 and continued his role as Chair of the Board of Directors. In light of the interim and limited duties as Executive Chair in 2023, Dr. Peter Wilden continues to be assessed as “non-executive”.
10 Ferring Group is disclosed in note 22 “Related parties” of the consolidated financial statements in the Financial Report 2024 as a related party because it is related to the Company through the Esperante Investments Group ownership structure. For further information, see note 22 “Related parties” of the consolidated financial statements in the Financial Report 2024.

Education

  • PhD in Economics, University of Kiel, Germany (1991)
  • MBA in Industrial Economics, University of Kiel, Germany (1986)
  • Education Tax Inspector at the German Inland Revenue Service, Germany (1977–1980)

Key skills: Industry experience; Leadership / management; Finance / accounting / risk management; Data / digital; Environmental, social and governance (ESG); Strategy / development / execution

Read More
graphic

Patrick Aebischer

Vice-Chair and Lead Independent Director since 202111
Non-executive
Nationality: Swiss
Year of birth: 1954

Professional background

Dr. Aebischer was the president of EPFL, the Swiss Federal Institute of Technology Lausanne from 2000 to 2016 and Professor of Neurosciences until his retirement in 2019. He has received numerous honors, including the Robert Bing Prize of the Swiss Academy of Medicine and the Pfizer Foundation Prize for Clinical Neurosciences. Dr. Aebischer holds various academic advisory positions as well as various positions in non-profit foundations and scientific advisory boards.

Prior positions at PolyPeptide

  • None

Outside mandates at listed companies

  • Member of the board of directors of Nestlé SA, Switzerland (since 2015)

Outside mandates at non-listed companies

  • Member of the board of directors of Swiss Vaccine SA, Switzerland (since 2022)
  • Chair of the board of directors of Vandria SA, Switzerland (since 2021)
  • Senior Partner of NanoDimension Management Limited, Cayman Islands (since 2017)
  • Chair of the board of directors of Amazentis SA, Switzerland (since 2007)
    11 Dr. Patrick Aebischer has been a Senior Partner and member of the Investment Advisory Committee of NanoDimension Management Limited since 2017. In 2021, PolyPeptide committed to a limited investment in a partnership managed by NanoDimension Management Limited. Dr. Aebischer abstained from voting on this item. The indirect business relationship between PolyPeptide and Dr. Aebischer resulting from this commitment is considered comparatively minor. Thus, Dr. Aebischer is regarded as independent within the meaning of art. 15 Swiss Code of Best Practice for Corporate Governance and section 4(d) of the Organizational Regulations.

    Outside mandates at non-profit organizations

    • Member of the board of directors of Fondation “Geneva Science & Diplomacy Anticipator”, Switzerland (since 2019)
    • Member of the board of directors of Fondation du domaine de Villette, Switzerland (since 2018)
    • Member of the board of directors of Fondation Defitech, Switzerland (since 2017)
    • Chair of the board of directors of Swiss Polar Foundation, Switzerland (since 2016)
    • Member of the board of directors of Fondation Claude Nobs, Switzerland (since 2015)
    • Member of the board of directors of Fondation du Festival de Verbier, Switzerland (since 2015)

    Former outside activities and functions

    • Member of the board of directors of Logitech SA, Switzerland (2016–2024)
    • Chair of the board of directors of Fondation ArtTech, Switzerland (2017–2024)
    • Chair of the board of directors of the Novartis Venture Fund, Switzerland (2014–2023)
    • Member of the board of directors of Lonza Group AG, Switzerland (2008–2020)
    • Professor of Neurosciences, Swiss Federal Institute of Technology Lausanne (EPFL), Switzerland (2000–2019)
    • President of EPFL, Switzerland (2000–2016)

    Education

    • Dr. in Medicine, University of Geneva, Switzerland (1983)
    • MD, University of Geneva, Switzerland (1980)

    Key skills: Industry experience; Leadership / management; Data / digital; Environmental, social and governance (ESG); Strategy / development / execution; Independence

    Read More
    graphic

    Erik Schropp

    Member since 2021
    Non-executive
    Nationality: Dutch
    Year of birth: 1964

    Professional background

    Currently, Mr. Schropp is CEO of Esperante Investments Group and a director of Draupnir Holding B.V. (one of the Company’s significant shareholders, see section 1.2 “Significant shareholders” of this Corporate Governance Report).12 As a result of these roles, Mr. Schropp is assessed as not independent.

    Prior positions at PolyPeptide

    • Member of the board of directors of PolyPeptide Laboratories Holding B.V., The Netherlands, and PolyPeptide Laboratories Holding (PPL) AB, Sweden (2017–2021)

    Outside mandates at listed companies

    • None

    Outside mandates at non-listed companies

    • CEO of Esperante Investments Group (since 2020) (including serving as a member of the board of directors of Draupnir Corporation B.V., The Netherlands (since 2022) and Draupnir Holding B.V., The Netherlands (since 2008) and of the following strategic business units: (i) SEVER Life Sciences B.V., The Netherlands (since 2019), including serving as a member of the board of directors of two subsidiary companies; (ii) Esperante Ventures B.V., The Netherlands (since 2008); (iii) Svar Life Science AB, Sweden (since 2008), including serving as a member of the board of directors of two subsidiary companies)
    • Member of the board of directors of Haydn Holding AB, Sweden (since 2012) (including serving as a member of the board of directors at six subsidiary companies)
    • Member of the board of directors of Ferring Foundation B.V., The Netherlands (since 2008) (including serving as a member of the board of directors of two subsidiary entities)

    Outside mandates at non-profit organizations

    • Member of the board of directors, Stichting Det Paulsen Legaat, The Netherlands (since 2023)
    • Member of the board of directors, Stichting Vrienden van Megara, The Netherlands (since 2022)

    Former outside activities and functions

    • Member of the board of directors of FinVector Oy, Finland (2020–2021)
    • Member of the board of directors of Altacor Ltd., United Kingdom (2014–2017)
    • Group Financial Officer, C&P Investors Group (presently: Esperante Investments Group), The Netherlands (2008–2020)
    • Group Tax & Finance Director, C&P Investors Group (presently: Esperante Investments Group), The Netherlands (2005–2008)
    • International Tax & Finance Director, Ferring Pharmaceuticals, The Netherlands and Denmark (1999–2005)
    12 Draupnir Holding B.V. is disclosed in note 22 “Related parties” of the consolidated financial statements in the Financial Report 2024 as a related party because it is related to the Company through the Esperante Investments Group ownership structure. For further information, see note 22 “Related parties” of the consolidated financial statements in the Financial Report 2024.

    Education

    • Master’s degree in Economics & Tax, Erasmus University, Rotterdam, The Netherlands (1988)

    Key skills: Leadership / management; Finance / accounting / risk management; Data / digital

    Read More
    graphic

    Jane Salik

    Member since 2021
    Independent; Non-executive
    Nationality: American
    Year of birth: 1953

    Professional background

    Ms. Salik joined PolyPeptide in 1996 as President of PolyPeptide Laboratories Inc., where she was responsible for sales and marketing, overall management, administration and strategic planning for the company. In 2006, she was appointed CEO, during which time she guided PolyPeptide through a period of significant growth, expansion of sales and profits, expanding into new geographies and establishing a culture of innovation and execution of best practice. Ms. Salik resigned as CEO on 29 April 2021 and was a member of the Executive Committee of PolyPeptide until 17 August 2021. Since her operational management roles at the Group ended more than three years ago, Ms. Salik is now assessed as independent.

    Prior positions at PolyPeptide

    • Group CEO (2006–April 2021) and Executive Committee member (2006–August 2021)
    • President, PolyPeptide Laboratories Inc., US (1996–2006)
    • Member of the board of directors of PolyPeptide Laboratories Holding B.V., The Netherlands, as well as certain of its direct and indirect global subsidiaries (2003–2021)

    Outside mandates at listed companies

    • None

    Outside mandates at non-listed companies

    • None

    Outside mandates at non-profit organizations

    • None

    Former outside activities and functions

    • Vice President of Sales and Marketing, Bachem California, US (1986–1996)
    • Technical services biochemist, product manager and marketing manager, Boehringer Mannheim, US (1980–1986)

    Education

    • PhD in Molecular and Cellular Biology, SUNY Stony Brook, US (1980)
    • B.A. in Biology, Lafayette College, US (1975)

    Key skills: Industry experience; Leadership / management; Environmental, social and governance (ESG); Strategy / development / execution; Independence

    Read More
    graphic

    Beat In-Albon

    Member since 2021
    Independent; Non-executive
    Nationality: Swiss
    Year of birth: 1952

    Professional background

    From 2016 to 2018, Mr. In-Albon was Head of Strategic Projects at Lonza AG, Switzerland, on a part-time basis ahead of his retirement. Previously, Mr. In-Albon served as Senior Vice President and Chief Operating Officer Specialty Ingredients and was a member of the Executive Management Committee of Lonza AG, Switzerland, from 2012 until 2015.

    Prior positions at PolyPeptide

    • None

    Outside mandates at listed companies

    • Member of the board of directors of Evolva Holding SA, Switzerland (since 2020, Chair 2020–2022)

    Outside mandates at non-listed companies

    • Chair of the board of directors of Hans Kalbermatten Thermalbad AG, Switzerland (since 2021)

    Outside mandates at non-profit organizations

    • Vice-Chair of the board of directors of Lonza Arena AG, Switzerland (since 2020)

    Former outside activities and functions

    • Member of the board of directors of Deccan Fine Chemicals Pvt. Ltd., India (2019–2023)
    • Member / Chair of the board of directors of Escientia Switzerland AG, Switzerland (2020–2021)
    • Head of Strategic Projects at Lonza AG, Switzerland (2016–2018)
    • Senior Vice President and COO Specialty Ingredients / Member of the Executive Management Committee, Lonza AG, Switzerland, (2012–2015)
    • Member of the board of directors of Siegfried AG, Switzerland (2009–2012)
    • Executive Vice President of Industrial Services, Member of the Operations Council, SGS SA, Switzerland (2009–2012)
    • Executive Vice President of Life Science Services / Member of the Operations Council, SGS SA, Switzerland (2008–2009)
    • Various positions at Lonza AG, Switzerland, (1983–2007), including Senior Vice President / Head of Organic Fine- & Performance Chemicals / Member of the Executive Management Committee (2003–2007)

    Education

    • Master of Business Administration in Political Economy, University of Fribourg, Switzerland (1987)
    • PhD in Economic Science, University of Fribourg, Switzerland (1983)

    Key skills: Industry experience; Leadership / management; Finance / accounting / risk management; Law / regulatory; Environmental, social and governance (ESG); Independence

    Read More
    graphic

    Philippe Weber

    Member since 2021
    Independent13; Non-executive
    Nationality: Swiss
    Year of birth: 1965

    Professional background

    Mr. Weber is a member of the board of directors of Niederer Kraft Frey AG, Zurich (since 2008) and has been a partner of Niederer Kraft Frey AG, Zurich since 2002. He is an attorney-at-law admitted to the Swiss bar.

    Prior positions at PolyPeptide

    • None

    Outside mandates at listed companies

    • Vice-Chair of the board of directors of Leonteq AG, Switzerland, and Leonteq Securities AG, Switzerland (both since 2020)
    • Member of the board of directors of Medacta Group AG, Switzerland (since 2019)
    • Member of the board of directors of EDAG Engineering Group AG, Switzerland (since 2015)

    Outside mandates at non-listed companies

    • Member of the board of directors of NorthStar Holding AG, Switzerland (since 2018)
    • Member of the board of directors of Banca del Ceresio SA, Switzerland (since 2017)
    • Member of the board of directors of Newron Suisse SA, Switzerland (since 2007)
    • Partner at Niederer Kraft Frey AG, Switzerland (since 2002)
    • Company Secretary of CLS Group Holdings AG, Switzerland (since 2002)

    Outside mandates at non-profit organizations

    • None

    Former outside activities and functions

    • Chair of the board of directors and managing partner of Niederer Kraft Frey AG, Switzerland (2015–March 2021)
    • Director of Robert Aebi AG, Switzerland (2004–2017)

    Education

    • PhD in law (summa cum laude), University of Zurich, Switzerland (1995)
    • LL.M. (with distinction), European University Institute (EUI) in Fiesole, Italy (1994)

    Key skills: Leadership / management; Law / regulatory; Environmental, social and governance (ESG); Strategy / development / execution; Independence

    13 Mr. Weber is a Partner at Niederer Kraft Frey AG (NKF); see section 4.2 “Compensation of the Board of Directors” of the Remuneration Report 2024 for disclosure of the fees paid to NKF for legal services in relation to ongoing corporate legal matters in 2024. The business relationship between PolyPeptide and NKF is considered minor. Thus, Mr. Weber is regarded as independent within the meaning of art. 15 Swiss Code of Best Practice for Corporate Governance and section 4(d) of the Organizational Regulations.
    Read More

    3.2 Other activities and vested interests

    Except as disclosed in the biographies of the members of the Board of Directors, no further activities or vested interests are carried out outside of PolyPeptide.

    3.3 Mandates and other permitted activities

    In accordance with Swiss law, our Articles of Association limit the number of functions in superior management or administrative bodies of legal units other than with PolyPeptide that Directors are allowed to hold at one time.

    Pursuant to art. 23 of the Articles of Association, the Directors may have the following comparable functions at other companies with an economic purpose (including their group):

    • up to four (4) mandates as member of the board of directors or any other superior management or administrative body of listed companies; and, in addition,
    • up to ten (10) mandates as member of the board of directors or any other superior management or administrative body of legal entities that do not meet the above mentioned criteria.

    With respect to the additional activities of the Directors, mandates in companies that are under uniform control or the same beneficial ownership are deemed to be one mandate.

    The following mandates shall not be subject to the limitations set forth in art. 23 of the Articles of Association:

    • mandates in companies which are controlled by the Company or which control the Company;
    • mandates held at the request of the Company or companies controlled by it; no member of the Board of Directors shall, however, hold more than ten (10) such mandates; and
    • mandates in associations, charitable organizations, foundations, employee welfare foundations and other similar organizations; no member of the Board of Directors shall, however, hold more than fifteen (15) such mandates.

    3.4 Election and term of office

    According to art. 15 of the Articles of Association, the Board of Directors consists of a minimum of three (3) members. As prescribed by Swiss Law, all members of the Board of Directors, including the Chair, have to be elected individually, and may only be removed by a shareholders’ resolution. The maximum term of office for a member of the Board of Directors is one year. In this context, one year means the time period between one general meeting and the next or, if a member is elected at an extraordinary shareholders’ meeting between such extraordinary shareholders’ meeting and the next general meeting. Re-election is possible. The Company’s Articles of Association do not contain a limitation on the number of terms served or the age of members of the Board of Directors, including the Chair. Furthermore, the Company’s Articles of Association do not contain any rules concerning the appointment of the Chair, the members of the Remuneration and Nomination Committee or the independent proxy (the “Independent Proxy”) that deviate from those prescribed by Swiss law.

    The members of the Remuneration and Nomination Committee (individually) as well as the Independent Proxy are also elected by the general meeting for a one-year term.

    If the office of the Chair of the Board of Directors is vacant, the Remuneration and Nomination Committee is not complete or the Company does not have an Independent Proxy, the Board of Directors shall appoint a substitute for the time period until the conclusion of the next general meeting who must be (with the exception of the Independent Proxy) a member of the Board of Directors.

    Please refer to section 3.1 “Members of the Board of Directors” of this Corporate Governance Report for information relating to the time of first election to office of the Company’s current Directors.

    3.5 Internal organizational structure

    3.5.1 Allocation of tasks within the Board of Directors

    3.5.1.1 General

    Our Board of Directors is responsible for the ultimate direction of PolyPeptide, supervision of our management and holds the ultimate decision-making authority, with the exception of matters reserved for shareholders.

    The Board of Directors determines PolyPeptide’s strategy, the allocation of resources and the management framework. It is also responsible for setting the organizational structure, accounting, financial control and financial planning. In addition, the Board of Directors takes responsibility for all sustainability and environmental, social and governance (“ESG”) issues. For further information, see section 2.2.5 of the Organizational Regulations and the Corporate Responsibility Report 2024.

    The internal structure of our Board of Directors is set out in the Organizational Regulations, which determines the corporate bodies of PolyPeptide, defines their responsibilities and competences regarding management and regulates the functioning and cooperation of the various bodies involved in PolyPeptide’s management. Subject to applicable law and the Articles of Association, the allocation of tasks within the Board of Directors is determined annually by the Board at its first meeting following the general meeting in accordance with section 2.1.1 of the Organizational Regulations. The Board of Directors regularly reviews the Organizational Regulations and makes any necessary amendments.

    To operate effectively and allow in-depth focus in specific areas, the Board of Directors has three standing committees (each, a “Committee”):

    Committee 1

    Chair

    Member

     

     

     

    Audit and Risk Committee (ARC)

    Erik Schropp 2

    Beat In-Albon

    Remuneration and Nomination Committee (RNC)

    Philippe Weber

    Peter Wilden

    Innovation and Technology Committee (ITC)

    Patrick Aebischer

    Jane Salik

    1 The Board of Directors decided to dissolve the Chair’s Committee (CC) at its meeting held on 1 July 2024. For further information, see section 3.5.3.4 “Chair’s Committee” of this Corporate Governance Report.
    2 The Board of Directors elected Erik Schropp as chair of the Audit and Risk Committee as of 11 April 2024.

    Except for the election of the Chair of the Board of Directors and the members of the Remuneration and Nomination Committee (which are to be elected by the general meeting), the Board of Directors determines its own organization. It elects from among one of the independent Directors the Lead Independent Director and the chair of the Remuneration and Nomination Committee (from among those Directors elected to the Remuneration and Nomination Committee at the general meeting). Furthermore, it elects the chair and members of the other Committees as well as appoints a secretary (who does not need to be a shareholder or a member of the Board of Directors).

    Each Committee generally comprises two or more members of the Board of Directors with its own charter governing its duties and responsibilities. These Charters are regularly reviewed and amended as required. The Committees have no decision-making authority of their own (unless provided with such authority by a special resolution of the Board of Directors) and generally act in advisory and preparatory capacities. The Board of Directors remains ultimately responsible for the tasks delegated to the Committees by Swiss law, the Articles of Association or the Organizational Regulations.

    The Board of Directors may form additional ad-hoc and standing committees for particular areas within the scope of its duties to deal with specific issues. In 2024, no additional ad-hoc or standing committees were formed.

    At least annually, the Board reviews its own performance, as well as the performance of each of the Committees. Such anonymous assessments seek to evaluate the Board’s contribution to the Group and determine whether each of the Board and the Committees function effectively and efficiently. In addition, these assessments aim to improve governance, identify gaps in skill sets and diversity, as well as define future priorities for the Group. The assessments are reviewed on an annual basis by the Remuneration and Nomination Committee, which periodically considers together with the Board an external evaluation. For 2024, the self-assessments were prepared by the Company based on customary industry evaluations and questionnaires. Following the completion of the assessments, the Board of Directors reviews the results and discusses areas or opportunities for improvement.

    3.5.1.2 Chair of the Board of Directors

    The Chair calls and chairs the meetings of the Board of Directors and presides over the general meetings. Together with the person keeping the minutes (i.e., the secretary), he or she signs the minutes of the deliberations and resolutions of the Board of Directors. The Chair, together with the CEO, is responsible for ensuring effective communication with shareholders and stakeholders, including government officials, regulators and public organizations. The Chair establishes and maintains a close working relationship with the CEO, providing advice and support to him or her. Furthermore, the Chair seeks to facilitate a constructive relationship between the Board of Directors, the CEO, and the other Board Committee members.

    The Chair has the right to call upon third parties as advisors in meetings of the Board. The Committees shall keep the Chair informed on a current basis about all important strategic issues, transactions, the business situation and development, and important organizational changes within their scope of responsibilities and duties. The Chair shall monitor such informational duty of the Committees. The Chair reports to the Board of Directors on information received from each of the Committees. In addition, the Chair shall immediately inform the other Directors of any extraordinary situation regarding the Company or the Group of which the Chair may become aware. Peter Wilden is currently serving as the Chair of the Board of Directors. For more information, see section 3 of the Organizational Regulations.

    3.5.1.3 Lead Independent Director

    The Lead Independent Director is an independent member of the Board of Directors and is elected by the Board of Directors until the conclusion of the next general meeting. If the Chair is indisposed, the Lead Independent Director will take the chair at the meetings of the Board of Directors and the shareholders’ meeting. In particular, the Lead Independent Director will chair the meeting of the Board of Directors or the shareholders’ meeting if the Chair is required to abstain from the deliberation and decision-taking in case the following items are on the agenda: (i) assessment of the work of the Chair; (ii) decision of the Board of Directors on the request to the shareholders’ meeting for the re-election or not of the Chair; (iii) decision about the compensation of the Chair; and (iv) any other matters in which the Chair has a conflict of interest. The Lead Independent Director is entitled to call a meeting of the Board of Directors whenever he or she deems fit. Patrick Aebischer is currently serving as the Lead Independent Director and Vice-Chair. For more information, see section 4 of the Organizational Regulations.

    3.5.2 Working methods of the Board of Directors

    3.5.2.1 Overview

    Meetings of the Board are held as often as the business requires, but as a general rule at least four (4) times per year, including (i) in the first quarter, inter alia, to approve the annual report, including the remuneration report and the report on non-financial matters, and the agenda and invitation to the upcoming general meeting; (ii) immediately after the general meeting, inter alia, to constitute the Board; (iii) in the third quarter, inter alia, to approve the half year financials; and (iv) in the fourth quarter, inter alia, to approve the budget for the next financial year. For each of these meetings, the Chair also generally selects key business or strategic topics for more in-depth focus and discussion, such as operations, customer developments, quality and risk management. Meetings of the Board are convened by the Chair if and when the need arises or whenever a Director or the CEO, indicating the reasons, so requests in writing. If the Chair does not comply with any such request within fourteen (14) days, the Lead Independent Director is entitled to call the meeting.

    Notice of meetings is given at least five (5) business days prior to the meeting. The notice must set forth the time, place and agenda of the meeting so that Directors may have a reasonable understanding of the business intended to be conducted at the meeting. Directors are provided with all necessary supporting materials at least five (5) business days prior to the meeting. In urgent cases (as determined by the Chair at his or her discretion), a meeting may be held at appropriate shorter notice. If the Chair deems it necessary, supporting materials may also be provided later to allow the Board to receive the latest available information. This applies, in particular, to updates on financial and other relevant data. Board meetings may be held in person, by telephone or by video conference.

    The Chair, or in his absence the Lead Independent Director, or in the absence of both, a Director designated by the attending Directors, shall chair the meeting.

    If all Directors are present and agree, deviations from the formal requirements set forth in the Organizational Regulations (including those described above) are permitted; in particular, decisions can be taken in respect of items that are not listed on the agenda for the meeting.

    In order to pass resolutions, not less than a majority of the Directors must be participating in the meeting (whether in person, by phone or video conference). The Board may pass its resolutions with the majority of the votes cast (simple majority). Abstentions count as votes uncast. In case of a tie of votes, the Chair has the casting vote. Board resolutions may also be passed by means of circular resolutions, by letter or electronic means (e.g., e-mail or via board management portals/platforms); provided that no Director requests by phone or e-mail within five (5) days of receipt of the proposed resolution that the resolution be deliberated in a meeting. Board resolutions by means of circular resolutions require the affirmative vote of the majority of the Directors.

    In principle (and as set forth in the Organizational Regulations), the CEO and the other members of the Executive Committee attend designated and selected sections of the meetings of the Board without the right to vote as guests, except where not appropriate (e.g., if particular matters relating to their performance or remuneration are discussed). For example, as a general matter, all members of the Executive Committee attend Board sessions dedicated to reports from management, whereas no members of the Executive Committee are present at the non-executive sessions of the Board meetings. Other members of the Group’s senior management are expected to participate at meetings of the Board if specific issues falling within their responsibility are on the agenda. The Chair decides if and which persons outside the Board are entitled to attend meetings of the Board as guests.

    The minutes set forth all resolutions passed and reflect in a general manner the considerations that led to the decisions taken, including, where applicable, any statements of attendees expressly made “for the record”. The minutes must be signed by the Chair (or, where applicable, the Director who chaired the meeting) and the secretary. The minutes are available for review prior to the next meeting of the Board of Directors, when it is approved. Resolutions passed by means of circular resolutions or telephone conference shall be included in the next minutes. Board Members are entitled to examine the minutes of any Board meeting (as well as any Committee meeting) at any time..

    As a general principle, Directors shall arrange their personal and business affairs so as to avoid, as much as possible, a conflict of interest. As set forth in the Organizational Regulations, each Director shall disclose to the Chair any conflict of interest arising from or relating to any matter to be discussed at the meeting of the Board as soon as the Director becomes aware of its potential existence. Directors should neither conclude any investment nor other transactions nor accept any benefits that may jeopardize their independent safeguarding of the Company’s interests.

    The Chair (or, if applicable, the Lead Independent Director or the Remuneration and Nomination Committee) will decide upon appropriate and commensurate measures to avoid any interference of such conflict of interests with the decision-making of the Company. In the event of doubt, the Chair (or, if applicable, the Lead Independent Director or the Remuneration and Nomination Committee) shall request the respective corporate body (under exclusion of the Directors who are subject to the potential conflict of interest) to determine whether a conflict of interest exists and to decide upon appropriate measures.

    As a rule, subject to exceptional circumstances in which the best interests of the Company dictate otherwise, in case of a disclosed conflict of interest, a two-stage vote regarding the matter at stake is to be held, first among all Directors and then without the Director subject to the conflict of interest. The Director with a conflict shall have the right to, or may be required by the Chair, to provide a statement of their view of the matter. In case of a continuing conflict of interest, the Board of Directors shall decide whether the Director subject to the conflict of interest should be asked to resign or should not be nominated for re-election (as the case may be).

    3.5.2.2 2024 Board of Director meetings and key topics

    Since 1 January 2024, the Board of Directors met nine (9) times, including a one-day strategy meeting, in a combination of in-person sessions and video conferences, for an average duration of approximately three and a half (3.5) hours (with individual sessions lasting between one (1) to over six (6) hours).

    The following table outlines the dates and the attendees of each meeting of the Board of Directors.

    Date / place

    Attendees

    Other attendees for relevant topics

     

     

     

    19 February 2024 Video conference

    Peter Wilden Patrick Aebischer Jane Salik Erik Schropp Beat In-Albon Philippe Weber Dorothee A. Deuring 1

    Juan José González Marc Augustin Neil Thompson (Director Global Sales and Marketing until 26 April 2024) Jens Fricke Christina Del Vecchio (Secretary)

    8 March 2024 Video conference

    Peter Wilden Patrick Aebischer Jane Salik Erik Schropp Beat In-Albon Philippe Weber Dorothee A. Deuring 1

    Juan José González Marc Augustin Christina Del Vecchio (Secretary)

    15 March 2024 Video conference

    Peter Wilden Patrick Aebischer Jane Salik Erik Schropp Beat In-Albon Philippe Weber Dorothee A. Deuring 1

    Christina Del Vecchio (Secretary)

    11 April 2024 Baar, Switzerland

    Peter Wilden Patrick Aebischer Jane Salik Erik Schropp Beat In-Albon Philippe Weber

    Juan José González Marc Augustin Jens Fricke Neil Thompson (Director Global Sales and Marketing until 26 April 2024) Monika Casanova (Chief Human Resources Officer) Christina Del Vecchio (Secretary)

    1 July 2024 Baar, Switzerland

    Peter Wilden Patrick Aebischer Jane Salik Erik Schropp Beat In-Albon Philippe Weber

    Juan José González Marc Augustin Jens Fricke Monika Casanova (Chief Human Resources Officer) Trishul Shah (Interim Director Global Sales and Marketing) Olivier Ludemann-Hombourger (Director Global Innovation and Technology) Jon Holbech Rasmussen (Director Global Quality, Development, Regulatory Affairs) Christina Del Vecchio (Secretary)

    2 July 2024 Baar, Switzerland

    Peter Wilden Patrick Aebischer Jane Salik Erik Schropp Beat In-Albon Philippe Weber

    Juan José González Marc Augustin Jens Fricke Monika Casanova (Chief Human Resources Officer) Trishul Shah (Interim Director Global Sales and Marketing) Olivier Ludemann-Hombourger (Director Global Innovation and Technology) Jon Holbech Rasmussen (Director Global Quality, Development, Regulatory Affairs) Christina Del Vecchio (Secretary)

    9 August 2024 Video conference

    Peter Wilden Patrick Aebischer Jane Salik Erik Schropp Beat In-Albon Philippe Weber

    Juan José González Marc Augustin Christina Del Vecchio (Secretary)

    3 September 2024 Braine-l’Alleud, Belgium

    Peter Wilden Patrick Aebischer Jane Salik Erik Schropp Beat In-Albon Philippe Weber

    Juan José González Marc Augustin Jens Fricke Michael Stäheli (Head of Investor Relations and Corporate Communications) Julien Coubran (Director Global EHS) Christina Del Vecchio (Secretary)

    26 November 2024 Baar, Switzerland

    Peter Wilden Patrick Aebischer Jane Salik Erik Schropp Beat In-Albon Philippe Weber

    Juan José González Marc Augustin Jens Fricke Rebeca Weil-Pflug (Head of Internal Audit) Julien Coubran (Director Global EHS) Christina Del Vecchio (Secretary)

    1 Dorothee A. Deuring did not stand for re-election as a member of the Board of Directors at the AGM 2024 and left the Board of Directors on 10 April 2024.

    The key topics of the Board of Directors during this period included, among other things:

    • Regular review and discussion regarding the Group’s year-to-date sales, operations, financials and full-year outlook as well as monitoring cash flow and net working capital
    • Review and approval of the Group’s 2024 budget
    • Review and approval of the Group’s strategy and mid-term business plan
    • Review and approval of the 2023 annual report, including the remuneration report and the report on non-financial matters, and audited consolidated financial statements
    • Review and approval of the 2023 variable short-term incentive for the members of the Executive Committee
    • Review and approval of the AGM 2024 agenda and invitation
    • Review and approval of the individual targets and weighting of 2024 variable short-term incentive as well as performance targets for the 2024 variable long-term incentive award for the members of the Executive Committee
    • Approval of removals from the Executive Committee
    • Approval of material business transactions and agreements
    • Approval of the 2024 half-year report and consolidated financial statements
    • Monitoring of developments with key customers and operational and profitability improvement initiatives
    • Review and monitoring of the Group’s Environmental, Social and Governance (ESG) Roadmap and accompanying non-financial reporting legal obligations, including the approval of the Group’s climate strategy and its transition plan
    • Review and approval of the Group’s Enterprise Risk Management Report 2024
    • Planning and content of the Group’s 2024 annual report and topics related to the 2025 general meeting
    • Review of the Group’s Articles of Association
    • Review and approval of revised Organizational Regulations and various other key governance and corporate policies
    • Review of the Group’s budget for 2025 financial year

    3.5.3 Working methods of the Committees

    The Committees act in advisory and preparatory capacities and have no decision-making authority of their own (unless provided with such authority by a special resolution of the Board of Directors). The Board remains ultimately responsible for the tasks delegated to the Committees by Swiss law, the Articles of Association or the Organizational Regulations.

    The Committees keep the Chair of the Board of Directors informed on a current basis about all important strategic issues, transactions as well as any business situations and / or developments within their scope of responsibilities and duties. The Chair monitors such informational duties of the Committees. The chair of each Committee provides the full Board of Directors at their meeting with an overview of key topics discussed at the most recent Committee meeting.

    Each Committee meets at such frequency as it deems necessary to fulfill its duties, normally ahead of ordinary Board meetings, which are expected to take place at least four times per year. Additional meetings may be held and may be convened at the request of either the Board of Directors or any Committee member. The Audit and Risk Committee further meets upon request of the governance, risk and compliance officer (the “GRC Officer”).

    The secretary prepares the agenda for each meeting, keeps the minutes, and assists the Committee and the chair to coordinate and fulfill their duties and assignments. Once signed by the Committee chair and secretary, the minutes (together with all presentation and background materials) of each Committee meeting are made available to the full Board of Directors for their review.

    3.5.3.1 Remuneration and Nomination Committee

    The Remuneration and Nomination Committee is entrusted with preparing and periodically reviewing PolyPeptide’s compensation policy, compensation strategy and principles as well as the performance criteria related to compensation and the accompanying review of their implementation. The Remuneration and Nomination Committee is also responsible for submitting proposals and recommendations to the Board of Directors regarding compensation matters. The Remuneration and Nomination Committee further supports the Board of Directors in preparing the compensation proposals for the general meeting. In addition, the Remuneration and Nomination Committee assists the Board of Directors in relation to the succession planning for and nomination of the members of the Board of Directors and the Executive Committee as well as the corporate governance of the Company and the Group. In furtherance of this, the Remuneration and Nomination Committee, for example, regularly assesses the set of competencies as well as each Director’s contributions to ensure that an appropriate mix of skills, expertise and diversity is represented on the Board of Directors and its Committees. The specific responsibilities and competencies of the Remuneration and Nomination Committee are set forth in art. 19 of the Articles of Association, section 5.3 of the Organizational Regulations as well as the Remuneration and Nomination Committee Charter.

    The members of the Remuneration and Nomination Committee are individually elected by the general meeting. The term of office of the members of the Remuneration and Nomination Committee ends at the conclusion of the next ordinary general meeting. Re-election is possible. The chair of the Remuneration and Nomination Committee shall be independent and is appointed by the Board of Directors. As of 31 December 2024, the Remuneration and Nomination Committee consisted of two members: Philippe Weber (chair) and Peter Wilden.

    2024 Remuneration and Nomination Committee meetings and key topics

    Since 1 January 2024, the Remuneration and Nomination Committee met six (6) times, in a combination of in-person sessions and video conferences, for an average duration of approximately one (1) hour.

    Date / place

    Attendees

    Other attendees for relevant topics

     

     

     

    13 February 2024 Video conference

    Philippe Weber Peter Wilden

    Juan José González Monika Casanova (Chief Human Resources Officer) Representatives from HCM International Ltd. Christina Del Vecchio (Secretary)

    1 March 2024 Video conference

    Philippe Weber Peter Wilden

    Juan José González Marc Augustin Monika Casanova (Chief Human Resources Officer) Representatives from HCM International Ltd. Christina Del Vecchio (Secretary)

    10 April 2024 Baar, Switzerland

    Philippe Weber Peter Wilden

    Monika Casanova (Chief Human Resources Officer) Christina Del Vecchio (Secretary)

    1 July 2024 Baar, Switzerland

    Philippe Weber Peter Wilden

    Juan José González Monika Casanova (Chief Human Resources Officer) Christina Del Vecchio (Secretary)

    2 September 2024 Braine-l’Alleud, Belgium

    Philippe Weber Peter Wilden

    Monika Casanova (Chief Human Resources Officer) Christina Del Vecchio (Secretary)

    25 November 2024 Baar, Switzerland

    Philippe Weber Peter Wilden

    Juan José González Monika Casanova (Chief Human Resources Officer) Christina Del Vecchio (Secretary)

    During the course of 2024, the key topics discussed by the Remuneration and Nomination Committee included, among other things:

    • General review and assessment of the continued appropriateness of PolyPeptide’s remuneration principles, strategy and structure
    • Review and preparation of compensation proposals for the Board of Directors and Executive Committee for AGM 2024
    • Finalization of the redesign of PolyPeptide’s long-term incentive program (LTIP), with a focus on the performance targets
    • Review of the Remuneration Report 2023
    • Review and preparation of proposals to the Board regarding the achievement of the 2023 variable short-term incentive for the members of the Executive Committee, including individual performance appraisal
    • Review and preparation of proposals to the Board regarding individual performance targets and weighting for the 2024 variable short-term incentive for the members of the Executive Committee
    • Review and preparation of proposals to the Board regarding of the performance targets for the 2024 variable long- term incentive award for the members of the Executive Committee
    • Review of shareholders’ and proxy advisors’ feedback on the Remuneration Report 2023
    • Review of the results of the remuneration benchmark desk research for the Board of Directors and Executive Committee
    • Succession planning and candidate recruitment for the Board of Directors
    • Review of succession strategy for PolyPeptide’s management
    • Review of the results of the self-assessments of the Board of Directors and its Committees and consideration of an external evaluation
    • General update on corporate governance trends and best practices as well as relevant regulatory developments
    • Review of shareholder analysis and outreach
    • Update on human capital management, including the Group’s human resources mid- and long-term plan and an overview of key people analytics
    • Review of material ESG topics assigned to the Remuneration and Nomination Committee
    • Review of the structure and approach to the Remuneration Report 2024, including analysis on remuneration disclosure
    • Review of the Remuneration and Nomination Committee Charter

    3.5.3.2 Audit and Risk Committee

    The Audit and Risk Committee supports the Board of Directors with respect to matters involving the financial and risk management aspects of governance, including the integrity of the Company’s and Group’s financial statements. The Audit and Risk Committee focuses on assessing the adequacy and effectiveness of the Group’s internal and prudential systems and controls in relation to both financial and non-financial risks. This includes compliance with legal and regulatory obligations, insurance and related matters. The Audit and Risk Committee will also obtain reasonable assurance with respect to the activities of the Internal Audit as well as evaluates the external auditors regarding the fulfillment of the necessary qualifications and independence according to the applicable legal provisions and makes proposals to the Board of Directors concerning the choice of the external auditors. The Audit and Risk Committee is further responsible for the pre-approval of the appointment and dismissal as well as the compensation for the Head of Internal Audit. The Audit and Risk Committee communicates at least once a year with the external auditor without the participation of management (in “private sessions”). The specific responsibilities and competencies, organization, functioning and reporting of the Audit and Risk Committee are set forth in section 5.2 of the Organizational Regulations as well as the Audit and Risk Committee Charter.

    The members of the Audit and Risk Committee are appointed by the Board of Directors. The chair of the Audit and Risk Committee shall be independent; however, the Board may decide if it is prudent and in the Company’s best interests to diverge from this principle. As of 31 December 2024, the Audit and Risk Committee consisted of two members: Erik Schropp (chair) and Beat In-Albon.

    2024 Audit and Risk Committee meetings and key topics

    Since 1 January 2024, the Audit and Risk Committee met six (6) times, in a combination of in-person sessions and video conferences, for an average duration of approximately two and a half (2.5) hours.

    Date / place

    Attendees

    Other attendees for relevant topics

     

     

     

    1 March 2024 Video conference

    Beat In-Albon Erik Schropp Dorothee A. Deuring 1

    Marc Augustin Juan José González Lalit Ahluwalia (Senior Advisor, Corporate Finance) René Vestergaard (Director, Corporate Finance) Jonas Lavik Sonne (Senior IFRS Group Controller, Corporate Finance) Rebecca Weil-Pflug (Head of Internal Audit) Michael Stäheli (Head of Investor Relations and Corporate Communications) René Füglister (Partner, BDO) Simon Oswald (Sustainability Assurance Lead, BDO) Roland Z’Roth (Sustainability Services Expert, BDO) Isilay Dagdelen (Legal Counsel, Secretary )

    10 April 2024 Baar, Switzerland

    Beat In-Albon Erik Schropp Dorothee A. Deuring 1

    Marc Augustin René Vestergaard (Director, Corporate Finance, VC) Jonas Lavik Sonne (IFRS Reporting Manager, Corporate Finance, VC) Rebecca Weil-Pflug (Head of Internal Audit) Andreas Liese (Corporate Compliance Manager) Thomas Gerd Hansen (Director Global IS/IT, VC) Krister Svärd (Chief Information Security Officer, Global IT Services, VC) Isilay Dagdelen (Legal Counsel, Secretary )

    1 July 2024 Baar, Switzerland

    Erik Schropp Beat In-Albon

    Marc Augustin Juan José González René Vestergaard (Director, Corporate Finance, VC) Jonas Lavik Sonne (IFRS Reporting Manager, Corporate Finance, VC) Tim Brandl (Head of Financial Planning and Analysis, Global Finance) Inas Khedher (Head of Operations Controlling, Global Finance, VC) Thomas Gerd Hansen (Director Global IS/IT, VC) René Füglister (Partner, BDO, VC) Isilay Sahin (Legal Counsel, Secretary )

    5 August 2024 Video conference

    Erik Schropp Beat In-Albon

    Marc Augustin Juan José González René Vestergaard (Director, Corporate Finance) Jonas Lavik Sonne (IFRS Reporting Manager, Corporate Finance) Tim Brandl (Head of Financial Planning and Analysis, Global Finance) Rebecca Weil-Pflug (Head of Internal Audit) René Füglister (Partner, BDO) Isilay Sahin (Legal Counsel, Secretary )

    2 September 2024 Braine-l’Alleud, Belgium

    Erik Schropp Beat In-Albon

    Marc Augustin Juan José González Christina Del Vecchio René Vestergaard (Director, Corporate Finance, VC) Andreas Liese (Corporate Compliance Manager) Julien Coubran (Director Global EHS) Thomas Gerd Hansen (Director Global IS/IT, VC) Lalit Ahluwalia (Senior Advisor, Corporate Finance, VC) Rebecca Weil-Pflug (Head of Internal Audit, Secretary )

    25 November 2024 Baar, Switzerland

    Erik Schropp Beat In-Albon

    Marc Augustin Juan José González René Vestergaard (Director, Corporate Finance, VC) Dick Palmqvist (Group Treasury, Global Corporate Finance, VC) Thomas Gerd Hansen (Director Global IS/IT, VC) Rebecca Weil-Pflug (Head of Internal Audit) René Füglister (Partner, BDO, VC) Isilay Sahin (Legal Counsel, Secretary )

    1 Dorothee A. Deuring did not stand for re-election as a member of the Board of Directors at the AGM 2024.

    During the course of 2024, the key topics discussed by the Audit and Risk Committee included, among other things:

    • Review of 2023 BDO audit and full-year consolidated and standalone financial statements and respective recommendations to the Board of Directors
    • Review of 2024 half-year consolidated financial statements and recommendation to the Board of Directors
    • Regular review and discussion regarding the Group’s year-to-date sales and financials as well as monitoring cash flow and net working capital
    • Monitor the Group’s long-term financing strategy
    • Review of the procedures and assumptions of the annual budgeting process and medium-term planning
    • Review of the work of Internal Audit, including compensation proposal for the Head of Internal Audit
    • Review of the Enterprise Risk Management Report 2024 and recommendations to the Board of Directors
    • Review of the Group’s compliance programs
    • Assessment and approval of the Group’s internal control system
    • Review of the Group’s insurance program and treasury policy
    • Assessment of the Group’s accounting policies as well as of tax and transfer pricing aspects
    • General assessment of yearly business expenses of the members of the Executive Committee
    • Review of the status of material legal proceedings, including measures taken by management to protect the interests of the Group
    • Evaluation of the Group’s external auditor and recommendation to the Board of Directors regarding re-election at AGM 2025, as well as pre-approval and oversight of all audit and non-audit services, budget and fees performed by the Group’s external auditors
    • Review of material ESG topics assigned to the Audit and Risk Committee and engagement of BDO for limited assurance on the Group’s report on non-financial matters for 2024
    • Review of the Audit and Risk Committee Charter and Internal Audit Charter

    3.5.3.3 Innovation and Technology Committee

    The Innovation and Technology Committee supports the Board of Directors and Executive Committee through the review of PolyPeptide’s technology plans and strategies, while monitoring existing and future trends in technology related or adjacent to PolyPeptide’s business. The specific responsibilities and competencies, organization, functioning and reporting of the Innovation and Technology Committee are set forth in section 5.4 of the Organizational Regulations as well as the Innovation and Technology Committee Charter.

    The members of the Innovation and Technology Committee are appointed by the Board of Directors. The chair of the Innovation and Technology Committee shall be independent. As of 31 December 2024, the Innovation and Technology Committee consisted of two members: Patrick Aebischer (chair) and Jane Salik.

    2024 Innovation and Technology Committee meetings and key topics

    Since 1 January 2024, the Innovation and Technology Committee met four (4) times, in a combination of in-person sessions and video conferences, for an average duration of approximately two (2) hours.

    Date / place

    Attendees

    Other attendees for relevant topics

     

     

     

    10 April 2024 Baar, Switzerland

    Patrick Aebischer Jane Salik

    Juan José González Neil Thompson (Director Global Sales and Marketing until 26 April 2024) Olivier Ludemann-Hombourger (Director Global Innovation and Technology) Andreas Lindgren (Director Global Development as of 1 July 2024, VC) Jon Holbech Rasmussen (Director Global Quality, Development, Regulatory Affairs, Secretary )

    27 June 2024 Video conference

    Patrick Aebischer Jane Salik

    Juan José González Olivier Ludemann-Hombourger (Director Global Innovation and Technology) Jon Holbech Rasmussen (Director Global Quality, Development, Regulatory Affairs, Secretary )

    2 September 2024 Braine-l’Alleud, Belgium 27 September 2024 Video conference

    Patrick Aebischer Jane Salik

    Juan José González Julien Coubran (Director Global EHS) Olivier Ludemann-Hombourger (Director Global Innovation and Technology) Jon Holbech Rasmussen (Director Global Quality, Development, Regulatory Affairs, Secretary )

     

     

     

    25 November 2024 Baar, Switzerland

    Patrick Aebischer Jane Salik

    Peter Wilden Juan José González Julien Coubran (Director Global EHS, VC) Trishul Shah (Interim Director Global Sales and Marketing, VC) Olivier Ludemann-Hombourger (Director Global Innovation and Technology, VC) Jon Holbech Rasmussen (Director Global Quality, Development, Regulatory Affairs, Secretary , VC)

    During the course of 2024, the key topics discussed by the Innovation and Technology Committee included, among other things:

    • Discussions on PolyPeptide’s green agenda, including the governance, priorities and objectives (i.e., green chemistry, green master plan and relevant KPIs)
    • Considerations regarding Process Excellence through clinical development
    • Discussions on the industrial challenges related to the implementation of new technologies and innovation in peptide development and manufacturing
    • Considerations and selected updates regarding strategic collaborations
    • Challenges for large scale manufacturing demands (e.g., GLP-1), presentation of an expansion strategy based on standard modular design
    • Review of material ESG topics assigned to the Innovation and Technology Committee
    • Review of the Innovation and Technology Committee Charter

    3.5.3.4 Chair’s Committee

    Following the completion of the onboarding of the new CEO during the second half of 2023 and first half of 2024, combined with the desire to improve the Board’s efficiency, the Board of Directors decided at its meeting held on 1 July 2024 to dissolve the Chair’s Committee. As required or necessary in the future, the Board may form additional ad-hoc and standing Board Committees for particular areas within the scope of its duties to deal with specific issues (see section 3.5.1.1 “General” of this Corporate Governance Report).

    Prior to its dissolution, the members of the Chair’s Committee included the Chair of the Board and the chairs of each Committee (i.e., the chair of the Remuneration and Nomination Committee, the chair of the Audit and Risk Committee and the chair of the Innovation and Technology Committee).

    2024 Chair’s Committee meetings and key topics

    From 1 January 2024 until its dissolution on 1 July 2024, the Chair’s Committee met four (4) times, in a combination of in-person sessions and video conferences, for an average duration of approximately one (1) hour.

    Date / place

    Attendees

    Other attendees for relevant topics

     

     

     

    18 January 2024 Video conference

    Peter Wilden Beat In-Albon Philippe Weber

    Juan José González Christina Del Vecchio (Secretary)

    4 March 2024 Video conference

    Peter Wilden Beat In-Albon Philippe Weber Patrick Aebischer

    Juan José González Christina Del Vecchio (Secretary)

    10 April 2024 Baar, Switzerland

    Peter Wilden Beat In-Albon Philippe Weber Patrick Aebischer

    Juan José González Christina Del Vecchio (Secretary)

    21 May 2024 Video conference

    Peter Wilden Erik Schropp Philippe Weber Patrick Aebischer

    Juan José González Christina Del Vecchio (Secretary)

    During the meetings held in 2024, the Chair’s Committee discussed various topics of strategic importance and other key business matters, including developments among the Group’s leadership team, long-term financing plans, developments with key customers as well as operational and profitability improvement initiatives.

    3.6 Areas of responsibility between the Board of Directors and the Executive Committee

    The Board of Directors’ responsibilities, duties and competencies and the procedural principles by which it is governed are specified by Swiss law, art. 17 of the Articles of Association and sections 2 through 5 of the Organizational Regulations. Importantly, the responsibilities of the Board of Directors include determining the strategy of PolyPeptide as well as the appointment, supervision and dismissal of the members of the Executive Committee.

    Art. 17 of the Articles of Association sets out the non-transferable and irrevocable duties of the Board of Directors, and in addition to the non-transferable and irrevocable duties set out in art. 716a CO, the Board of Directors has the further non-transferable and irrevocable duties to (i) prepare the report on non-financial matters and other reports as required by law, (ii) organization of the internal control system (ICS) and performance of the risk assessment, (iii) adopt resolutions and amendments to the Articles of Association regarding the subsequent payment of capital with respect to non-fully paid-in shares, (iv) adopt resolutions on the change of the share capital to the extent such power is vested in the Board of Directors, confirming changes in the share capital and adopt the consequential amendments to the Articles of Association (including deletions), (v) examine compliance with the legal requirements regarding the appointment / election of the external auditors, and (vi) execute the agreements pursuant to art. 12, 36 and 70 of the Federal Act on Merger, Demerger, Transformation and Transfer of Assets (Merger Act).

    While the Board of Directors is responsible for PolyPeptide’s ultimate strategic direction and supervision of management, through the Organizational Regulations the Board has delegated the responsibility and authority necessary or appropriate for carrying out the day-to-day and operational activities of PolyPeptide to the Executive Committee under the leadership of the CEO. Nevertheless, the Board of Directors retains certain duties (in addition to the non-transferable and irrevocable duties described above), such as annually approving the budgets and business plans for the Group, monitoring risks as well as ensuring that fundamental policies and controls are in place for compliance with applicable law and regulations. In addition, the Organizational Regulations set out specific parameters, including financial thresholds, for certain strategic, operational and financial matters that remain within the competence of the Board of Directors. This information is also set out in an authority chart, which is an annex to the Organizational Regulations.

    The Executive Committee is responsible for ensuring the execution of the decisions of the Board of Directors and implementing the strategy of PolyPeptide in accordance with Swiss law, the Articles of Association, the Organizational Regulations and the resolutions of the shareholders’ meeting. The Executive Committee is led by the CEO and as of 31 December 2024, it comprised the CEO, the CFO, the Director Global Operations and the General Counsel. The Executive Committee may include other officers as may be determined by the Board of Directors, in consultation with the CEO, from time to time. The Executive Committee has a dual function in the management of PolyPeptide. On the one hand, under the leadership of the CEO, the Executive Committee is responsible for the day-to-day business of the Company (to the extent not reserved to the Board); and, on the other hand, it is responsible for the operational business of the whole Group as well as of each individual site and subsidiary (to the extent that the respective competences are not reserved to the Board pursuant to the Organizational Regulations or are, by law, reserved to the boards of directors of the subsidiaries).

    Pursuant to the Organizational Regulations, the CEO is appointed and removed by the Board of Directors upon recommendation of the Remuneration and Nomination Committee. The other members of the Executive Committee are appointed and removed by the Board of Directors upon recommendation of the Remuneration and Nomination Committee and in consultation with the CEO.

    3.7 Information and control instruments vis-à-vis the Executive Committee

    3.7.1 Principles of Board information

    The Board of Directors has different information instruments in place to oversee, monitor and control the implementation of PolyPeptide’s strategy as well as the execution of the responsibilities delegated to the Executive Committee.

    Specifically, the Organizational Regulations require the CEO, together with the other members of the Executive Committee, to regularly inform the Board and its Committees at its ordinary meetings on the current course of business and all major business matters and important business developments, including anticipated opportunities and risks. Specifically, a report from the CEO is a standing agenda item at each ordinary board meeting where the CEO provides insight on the development of the Group’s business and key strategic initiatives.

    In addition, the Chair and the CEO are in contact at regular intervals with respect to all major corporate policy issues. Extraordinary matters, including significant unanticipated developments, must immediately be reported to the Chair. In addition, the Directors shall be informed immediately of extraordinary events by way of circular letter and, if necessary, in advance by telephone or e-mail.

    Furthermore, each Director is entitled to request information concerning all of PolyPeptide’s affairs reasonably necessary to fulfill their fiduciary duties. For Directors requiring information or wishing to review documents outside of ordinary Board meetings, the Director must address their request in writing (including by e-mail) to the Chair. To the extent necessary to fulfill their duties, each Director may further request in writing (including by e-mail) that the Chair authorizes the inspection of the books and records of the Company. If the Chair rejects a request for information, hearing or inspection, the Lead Independent Director or the Board shall decide whether to grant such request.

    3.7.2 Regular reports to the Board

    As noted above, the Executive Committee regularly reports to the Board of Directors and its Committees at their respective ordinary meetings. In addition to these meetings, on a monthly basis, the Board of Directors receives sales and financial reports with (i) an executive summary, (ii) an assessment of the Group’s monthly and year-to-date revenue, (iii) the profit and loss statement, the balance sheet and the cash flow statement, (iv) overview of inventory and net working capital as well as (v) selected Group KPIs, updates on various initiatives and the Group’s outlook. These monthly reports illustrate the actual financial results to date, along with comparisons to the previous period and the budgeted amounts, all with accompanying commentaries (where relevant). Directors often react to these reports with questions that are responded to by the CFO. Through the Audit and Risk Committee, the Board also receives the reports of PolyPeptide’s external auditor in connection with the audit of the full-year financial statements and the review and procedures performed on the half-year financial statements.

    3.7.3 Enterprise Risk Management Framework

    The Audit and Risk Committee, together with the CFO, the General Counsel and members of the finance team, have implemented an Enterprise Risk Management Framework. While the Board of Directors retains the ultimate responsibility for risk management and for determining the appropriate level of risk that PolyPeptide is willing to accept, the PolyPeptide Management Committee (together with the Audit and Risk Committee) is responsible for ensuring that the operation of the Enterprise Risk Management Framework is sound, including risk management of significant risks through the monitoring of specified actions.

    The Enterprise Risk Management Framework is designed to provide a consistent, Group-wide perspective of key risks as well as any other and emerging risk areas as they are identified in connection with ongoing monitoring and updates by risk owners and other stakeholders on an ongoing basis. The objective of these risk assessments is to (i) make the principal risks to which PolyPeptide is exposed more transparent, (ii) determine treatment measures to control, eliminate and / or exploit the level of the risks / opportunities while monitoring their effectiveness and (iii) ultimately improve risk management. This concept aims to ensure alignment between risk management practices and strategic objectives. To the extent that the ongoing evaluation of the Enterprise Risk Management Framework discovers significant unanticipated developments, the PolyPeptide Management Committee will immediately report these to the Audit and Risk Committee and the Chair of the Board. The Directors must also be informed of extraordinary events (as described above).

    The PolyPeptide Management Committee, together with the General Counsel, the Head of Internal Audit, the Corporate Compliance Manager and other internal stakeholders, annually conduct a risk assessment to identify risks, map probability and impact, and evaluate strategies to address the risks and opportunities identified (e.g., mitigating / managing actions). These mitigating / managing actions are specific to each identified risk and opportunity, and the respective risk owners are responsible for monitoring their implementation and effectiveness. The PolyPeptide Management Committee oversees the Enterprise Risk Management Framework throughout the year.

    Based on the annual risk assessment, an Enterprise Risk Management Report is prepared, specifying and assessing the main Group risks in terms of their probability and consequences as well as outlining the mitigating / managing actions, and submitted at least once per year to the Audit and Risk Committee. In addition, the Enterprise Risk Management Report is presented to the Board of Directors at one of their annually scheduled meetings for a deep-dive focus and discussion on risk assessment and management. In 2024, the deep-dive session and approval of the Enterprise Risk Management Report 2024 took place on 26 November 2024. In the Enterprise Risk Management Report 2024, PolyPeptide identified, inter alia, operational, supply chain, commercial, talent management and innovation risks for which corresponding risk mitigation / managing measures were adopted.

    See also chapter Business Review and note 23 “Financial risk management objectives and policies” of the consolidated financial statements in the Financial Report 2024.

    3.7.4 Internal controls

    The Board of Directors is also responsible for designing, implementing and maintaining the Group’s internal control system, which provides the ultimate oversight for PolyPeptide’s strategy, operations and finances. Importantly, the internal control system aims to ensure the integrity and completeness of accounting, to provide timely and reliable financial reporting, and to prevent, minimize and identify errors and irregularities in the financial statements. The Audit and Risk Committee supports the Board of Directors through the assessment of the adequacy and effectiveness of the Group’s internal and prudential systems and controls in respect of both financial and non-financial risks, including through discussions with and reviewing reports from the external auditor, internal officers and management. PolyPeptide’s internal control system is structured to ensure the correct disclosure and adequate coverage of control over all Group activities, with particular attention on areas considered potentially at risk. The external auditor confirms the existence of the internal control system in connection with the year-end audit.

    According to the Organizational Regulations, the CFO, in cooperation with the CEO, ensures good financial governance, overseeing all financial planning, budgeting (short- and mid-term), reporting and risk management activities. Furthermore, the CFO leads the implementation of systems and procedures to seek compliance with regulatory requirements for financial information, reporting, disclosure requirements and internal control. The CFO and the Audit and Risk Committee regularly evaluate the risks of material misstatements in the consolidated financial statements and assess if the risks are reduced to an acceptable level by established and planned mitigating controls and processes. Significant risks are also continuously discussed in the meetings of the Executive Committee, the PolyPeptide Management Committee and the Audit and Risk Committee, which all take place on a regular basis. In 2024, the Audit and Risk Committee focused on six key areas of internal controls, specifically (i) revenue, (ii) inventories, (iii) payroll, (iv) property, plant and equipment, (v) financial reporting and closing processes and (vi) valuation of participations. During the course of 2024, the Audit and Risk Committee, together with the CFO and members of the finance team, evaluated key risks of financial misstatements in the identified key areas together with mitigating controls / processes currently in place, all of which were reviewed by the external auditor. In addition, improvement suggestions are submitted by the external auditor on a yearly basis, which are implemented by management in the following year.

    3.7.5 Internal Audit

    In 2024, the Board of Directors, through the Audit and Risk Committee, was further supported by the Internal Audit function within PolyPeptide led by the Head of Internal Audit. Internal Audit’s mission is to ensure that PolyPeptide’s operations are conducted according to high standards by providing an independent, objective assurance function and by advising on best practices. Through a systematic and disciplined approach, Internal Audit helps PolyPeptide accomplish its objectives by evaluating and improving the effectiveness of the Group’s risk management, control and governance processes. As is customary across the industry, the evaluation and internal audit of PolyPeptide’s cGMP activities remain with the Quality department under the supervision of the Director Global Quality, Development, Regulatory Affairs.

    Internal Audit is responsible for, among other things, (i) developing and implementing annual internal audit plans using appropriate risk-based methodology, (ii) evaluating and assessing significant merging / consolidating of functions and new or changing services, processes, operations, technologies and control processes at the time of their development, implementation or expansion, (iii) establishing an Internal Audit quality assurance program to ensure high standards of operations, (iv) issuing periodic reports to the Audit and Risk Committee as well as the Executive Committee, (v) participating in any investigations at PolyPeptide and (vi) recommending appropriate actions to correct any deficiencies identified. The Audit and Risk Committee reviews and approves the annual internal audit plan. Further information on the responsibilities of Internal Audit can be found in the Internal Audit Charter, which is an annex to the Organizational Regulations. Functionally, the Internal Audit department reports to the Audit and Risk Committee. Administratively, the Internal Audit department reports to the CFO.

    During the course of 2024, Internal Audit with the support of external consultants performed one site audit as well as process audits across five sites. The audit reports are distributed to the Audit and Risk Committee, Executive Committee, relevant PolyPeptide Management Committee Members, the employees defined as owners of the findings, their line manager and the external auditor. All reports and related findings are presented and discussed during the Audit and Risk Committee scheduled meetings. The audit results as well as the results of other consultative projects conducted during 2024 were presented to the Audit and Risk Committee between the second and fourth quarters of 2024. As part of the Audit and Risk Committee’s regularly scheduled meetings, the Head of Internal Audit provides (i) progress updates on the approved audit plan and proposes any modifications to the audit plan if risk priorities change and (ii) provides information on the status of management’s corrective actions. See also section 3.5.3.2 “Audit and Risk Committee” of this Corporate Governance Report.

    3.7.6 Compliance controls

    PolyPeptide is committed to the highest levels of ethics and integrity in the way that it does business and understands that this is crucial for its continued success and reputation. PolyPeptide’s core values and Code of Business Conduct and Ethics guide its everyday conduct. To monitor these efforts, the General Counsel shall be or shall designate another person as the Group’s governance, risk and compliance officer (“GRC Officer”). Currently, the General Counsel serves as the GRC Officer.

    The GRC Officer is responsible for developing and maintaining compliance policies, promoting a culture of responsibility, maintaining risk management, identifying remediation needs, providing training and taking other steps to assist the Group in meeting its legal, regulatory and ethical obligations. The GRC Officer reports to the CEO. However, the GRC Officer also has direct access to the Audit and Risk Committee and reports to the Audit and Risk Committee whenever requested or if there exists a significant compliance or risk issue that involves or implicates a member of the Executive Committee that the GRC Officer believes cannot be or has not been appropriately addressed by, or directly implicates, the CEO.

    PolyPeptide has implemented various compliance initiatives and is continuously expanding these to respond to PolyPeptide’s ever-changing dynamic business environment. For example, in August 2022, PolyPeptide constituted a cross-functional Corporate Compliance Committee (the “CCC”) to promote compliance across the organization with a focus on corporate compliance issues and matters, including compliance with securities laws and regulations, data privacy as well as sanctions and trade. In 2024, membership of the CCC was expanded to ensure relevant cross-functional representation. The GRC Officer, or a delegate of the GRC Officer, is responsible for reporting on at least a quarterly basis (or more frequently, as needed) to the Executive Committee and the Audit and Risk Committee. Furthermore, in the second half of 2024 PolyPeptide updated its Code of Business Conduct and Ethics with a focus on addressing conflicts of interest and updated its Global Supply Chain Policy on Child Labor. PolyPeptide also updated its electronic learning tools aimed at reinforcing the principles set out in its Code of Business Conduct and Ethics and whistleblower policies.

    In addition, PolyPeptide has established and promotes its whistleblower programs and hotlines, where anybody with knowledge or suspicion of illegal activities or irregularities at PolyPeptide can report these observations confidentially and even anonymously. To ensure independence, PolyPeptide has mandated the operation of its whistleblower hotlines to a third-party service provider. The Group received ten whistleblower reports in 2024 (2023: two). During 2024, the investigation for seven reports has been closed and summarized to the Executive Committee and the Audit and Risk Committee, with a summary submitted to the Board of Directors. Four out of seven closed reports were partially or fully substantiated with appropriate actions taken and three closed reports were not substantiated. The investigation for the remaining three reports is still ongoing.

    The implementation of these and other compliance measures is supervised by and regularly reported to the Audit and Risk Committee at each of their ordinary meetings.

    3.7.7 Quality assurance

    To oversee and monitor PolyPeptide’s quality assurance, the CEO has designated this responsibility to the Director Global Quality, Development, Regulatory Affairs who reports to the CEO and is part of the PolyPeptide Management Committee. The Director Global Quality, Development, Regulatory Affairs supervises, inter alia, the Group’s quality control and quality assurance functions and is responsible for setting, reviewing, monitoring, revising and implementing the Group’s quality management, quality control systems and quality assurance programs to comply with regulatory requirements and ensure high quality products, processes and related customer support. In addition, the Director Global Quality, Development, Regulatory Affairs is responsible for, inter alia, providing results-oriented leadership to sustain and improve an effective and efficient international quality organization comprised of quality operations, quality systems, supplier quality and quality control / analytical development subject matter domains. The Director Global Quality, Development, Regulatory Affairs provides periodic updates to the Board. As of 31 December 2024, Jon Holbech Rasmussen was serving as the Director Global Quality, Development, Regulatory Affairs.

    3.8 Gender guidelines

    As of 31 December 2024, one (1) out of six (6) members of the Board of Directors was female (17%). The Remuneration and Nomination Committee, together with the Board of Directors, actively considers gender diversity in succession planning of the Board of Directors.